VBI Vaccines Inc. (VBIV)

0.53
NASDAQ : Health Technology
Prev Close 0.54
Day Low/High 0.51 / 0.54
52 Wk Low/High 0.47 / 2.39
Avg Volume 1.88M
Exchange NASDAQ
Shares Outstanding 178.26M
Market Cap 96.15M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
VBI Vaccines Announces Late-Breaker Oral Presentation At IDWeek 2019™

VBI Vaccines Announces Late-Breaker Oral Presentation At IDWeek 2019™

VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company's abstract titled, "Trivalent hepatitis B (HepB) vaccine...

VBI Vaccines Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

VBI Vaccines Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its previously announced underwritten public...

VBI Vaccines Announces Pricing Of $35 Million Public Offering

VBI Vaccines Announces Pricing Of $35 Million Public Offering

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the pricing of its previously announced underwritten public...

VBI Vaccines Announces Proposed Public Offering Of Common Shares

VBI Vaccines Announces Proposed Public Offering Of Common Shares

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an underwritten public offering of its...

VBI Vaccines Announces Phase 2a Clinical Evaluation Of VBI-1901 Cancer Vaccine Candidate In Combination With GSK's AS01B Adjuvant System In Recurrent Glioblastoma Patients

VBI Vaccines Announces Phase 2a Clinical Evaluation Of VBI-1901 Cancer Vaccine Candidate In Combination With GSK's AS01B Adjuvant System In Recurrent Glioblastoma Patients

VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the...

VBI Vaccines Announces Second Quarter 2019 Financial Results And Provides Corporate Update

VBI Vaccines Announces Second Quarter 2019 Financial Results And Provides Corporate Update

Positive top-line data from PROTECT Phase 3 for Sci-B-Vac ®, trivalent hepatitis B vaccine, announced June 2019 - top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019 ASCO presentation illustrated encouraging data from Part A...

VBI Vaccines Announces Dosing Of First Recurrent GBM Patient In Part B Of Ongoing Phase 1/2a Study Of VBI-1901

VBI Vaccines Announces Dosing Of First Recurrent GBM Patient In Part B Of Ongoing Phase 1/2a Study Of VBI-1901

— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded immunologic data and tumor and clinical responses...

Short Interest In VBI Vaccines Plummets 50.3%

Short Interest In VBI Vaccines Plummets 50.3%

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 427,415 share decrease in total short interest for VBI Vaccines Inc , to 423,005, a decrease of 50.26% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

VBIV: Insiders vs. Shorts

VBIV: Insiders vs. Shorts

The most recent short interest data was recently released for the 12/29/2017 settlement date, and VBI Vaccines Inc is one of the most shorted stocks of the Russell 3000, based on 6.89 "days to cover" versus the median component at 4.65. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Short Interest Moves 153.4% Higher For VBIV

Short Interest Moves 153.4% Higher For VBIV

The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 561,113 share increase in total short interest for VBI Vaccines Inc , to 926,804, an increase of 153.44% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: HDSN, MTR, SJT Downgrades: BOJA, CMCO, DM, KFRC, LEE, SENEA, SENEB, VBIV Initiations: ABIL Read on to get TheStreet Quant Ratings' detailed report:

VBI Vaccines Enters Oversold Territory (VBIV)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASRV, LOGM, QDEL, UHT Downgrades: NSEC Initiations: VBIV Read on to get TheStreet Quant Ratings' detailed report:

VBI Vaccines Emerges as Strong Biotech Stock

VBI Vaccines Emerges as Strong Biotech Stock

Armed with an arsenal of vaccines in its product pipeline, this small biotech company is ready to rocket.

Still Watching Price Action, but Playing Strong Defense

Still Watching Price Action, but Playing Strong Defense

The S&P 500 is hitting intraday lows, and I'm watching whether the market can rally again this afternoon.

Is This The Best Biotech Play for 2017?

Is This The Best Biotech Play for 2017?

Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?

Likely Clinton Victory Has Created an Opportunity for This Stock

Likely Clinton Victory Has Created an Opportunity for This Stock

In the early 1990s, Hillary Clinton's health care plan created a buying opportunity in related stocks. Now a similar situation is occurring.

TheStreet Quant Rating: D (Sell)